Engineered immune cells take on liver cancer in early trial
Disease control
Recruiting now
This early-phase study tests a new treatment called HRYZ-T102 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells that produce a pro…
Phase: PHASE1 • Sponsor: Shanghai Ruiliyuan Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 12, 2026 13:39 UTC